During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

An expert emphasizes that genomic profiling—including both germline and somatic testing—is now essential in metastatic prostate cancer management because it identifies key mutations such as homologous ...

An expert discusses recent trial data showing that combining radium-223 with enzalutamide modestly improves outcomes in metastatic castration-resistant prostate cancer (mCRPC) with bone ...